William Blair, Sofi
Denali Therapeutics’ (DNLI) Outperform Rating Reiterated at William Blair
William Blair reaffirmed their outperform rating on shares of Denali Therapeutics (NASDAQ:DNLI – Free Report) in a report published on Wednesday,RTT News reports. Other equities research analysts also recently issued research reports about the company.
Research analysts at William Blair issued their Q2 2025 EPS estimates for shares of Affirm in a research report issued to ...
William Blair has upgraded CVRx (NASDAQ:CVRX) to outperform from market perform, citing utilization improvements and ...
For investors looking for opportunities in fintech, SoFi presents an interesting case. Here's where analysts think the stock ...
Stock Trading Recap. On Friday, Tenaya Therapeutics Inc (TNYA) stock saw a modest uptick, ending the day at $1.4 which represents a slight increase ...
CHICAGO, January 07, 2025--(BUSINESS WIRE)--William Blair, the premier global boutique with expertise in investment banking, investment management, and private wealth management, has named Stewart ...
Neumora Therapeutics’ phase 3 fail was worse than analysts feared. | Neumora Therapeutics’ phase 3 fail was worse than ...
Republic Services Inc (RSG) stock saw a modest uptick, ending the day at $213.73 which represents a slight increase of $1.81 or 0.85% from the prior close of $211.92. The stock opened at $212.47 and ...
Equities research analysts at William Blair cut their Q4 2025 earnings per share estimates for shares of Karooooo in a report ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback